Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(21)
BIOLOGICAL(3)
GENETIC(1)
PROCEDURE(1)
laboratory biomarker analysis
4 trials
phase_1phase_1_2phase_2
university-of-washington
HER-2/neu peptide vaccine
3 trials
phase_1phase_1_2phase_2
university-of-washington
flow cytometry
3 trials
phase_1phase_1_2
university-of-washington
immunoenzyme technique
2 trials
phase_1phase_2
university-of-washington
denileukin diftitox
2 trials
phase_1phase_1_2
university-of-washington
enzyme-linked immunosorbent assay
2 trials
phase_1phase_1_2
university-of-washington
rintatolimod
1 trial
phase_1_2
university-of-washington
intraperitoneal administration
1 trial
phase_1
university-of-washington

+8 more interventions

16 unique interventions4 categories

Analytics

Trial Phases

Phase 14
Phase 24

Trial Status

Completed4
Terminated1
Other1

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT00425672Phase 1/2Completed
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
Male Breast CancerRecurrent Breast CancerStage IIIA Breast Cancer+3 more
PrincipalinvestigatorStart date: 2005-09-01
NCT00357448Phase 1Completed
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
Fallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid Adenocarcinoma+8 more
Principalinvestigator
NCT00821964Phase 2Completed
Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Male Breast CancerRecurrent Breast CancerSkin Metastases+1 more
Principalinvestigator
NCT01219907Phase 1Withdrawn
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
HER2-positive Breast CancerMale Breast CancerStage IV Breast Cancer
Principalinvestigator
NCT01355393Phase 1/2Completed
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+5 more
Principalinvestigator
NCT01729884Phase 2Terminated
Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Male Breast Cancer5Stage IV Breast Cancer5Recurrent Breast Cancer4HER2-positive Breast Cancer3Stage IIIA Breast Cancer2Stage IIIB Breast Cancer2Stage IIIC Breast Cancer2Fallopian Tube Cancer1

Affiliations

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Ingrid Mayer, MD

Vanderbilt-Ingram Cancer Center

Related
13 trials

Shared therapeutic areas:

Fallopian Tube CancerPeritoneal Cavity CancerStage IIIA Breast Cancer+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Vincent Chung

City of Hope Medical Center

Related
9 trials

Shared therapeutic areas:

Fallopian Tube CancerPeritoneal Cavity CancerRecurrent Breast Cancer+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Norman Wolmark, MD

NSABP Foundation Inc

Related
54 trials

Shared therapeutic areas:

Stage II Breast CancerStage IIIA Breast CancerStage IIIB Breast Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score6%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Breast CancerRecurrent Breast Cancer
Similarity Score3%

Virginia Sun

City of Hope Medical Center

Related
10 trials

Shared therapeutic areas:

Recurrent Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Leona A. Holmberg, MD, PhD

Fred Hutchinson Cancer Center

Related
10 trials

Shared therapeutic areas:

Peritoneal Cavity CancerFallopian Tube Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Franco M. Muggia, MD

NYU Langone Health

Related
9 trials

Shared therapeutic areas:

Fallopian Tube CancerPeritoneal Cavity Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Scott Holden, M.D.

Genentech, Inc.

Related
8 trials

Shared therapeutic areas:

Fallopian Tube Cancer
Similarity Score2%

Robert Kreitman, MD

National Cancer Institute (NCI)

Related
8 trials

Shared therapeutic areas:

Fallopian Tube Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Paul Sabbatini, MD

Memorial Sloan Kettering Cancer Center

Related
14 trials

Shared therapeutic areas:

Fallopian Tube Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT00425672Phase 1/2PrincipalInvestigator

ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment

Male Breast CancerRecurrent Breast CancerStage IIIA Breast Cancer+3 more
Completed
NCT00357448Phase 1PrincipalInvestigator

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer

Fallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid Adenocarcinoma+8 more
Completed
NCT00821964Phase 2PrincipalInvestigator

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Male Breast CancerRecurrent Breast CancerSkin Metastases+1 more
Completed
NCT01219907Phase 1PrincipalInvestigator

Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

HER2-positive Breast CancerMale Breast CancerStage IV Breast Cancer
Withdrawn
NCT01355393Phase 1/2PrincipalInvestigator

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+5 more
Completed
NCT01729884Phase 2PrincipalInvestigator

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
Terminated

All 6 trials loaded